Patent US4772591A successfully refreshed from Google Patents.
US4772591A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for accelerated wound healing
Assignee: Bioderm Inc
•
Filing: 1986-04-16
•
Granted: 1988-09-20
•
Expires: 2006-04-16
Abstract
Abstract A method and composition for accelerating the healing of wounds in animals and humans is disclosed. The method comprises administration of ascorbic acid, a source of biologically available calcium, a precursor or stimulant of epinephrine or nor-epinephrine selected from tyrosine and phenylalanine, and an anti-inflammatory substance selected from anti-inflammatory sugars, amino sugars and biocompatible acid addition salts thereof, and anti-inflammatory amino acids. Treatment in accordance with the present method reduces or prevents tissue degenerative effects of the inflammation associated with the natural wound healing process and promotes connective tissue (scar tissue) growth in the wound.
Inventors
- 👤 Lorraine F. Meisner
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 17:36
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/7004; A61K33/00; A61K33/06; A61K33/10; A61K33/42; A61K35/00; A61K35/12; A61K35/32; C; C07; C07H; C07H13/00; C07H13/02; C07H13/04
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
183 words
A method for accelerating wound healing in an animal or human having a wound in body tissue caused by trauma or surgery, which method comprises administration of the following substances in the relative weight proportions indicated: ascorbic acid, 1 to 5 parts; biologically available calcium, 2 to 10 parts provided by a calcium source selected from the group consisting of bone meal, biologically compatible calcium salts and calcium-containing foods; a precursor or stimulant of epinephrine or nor-epinephrine selected from tyrosine and phenylalanine, 0.5 to 2.5 parts; and an anti-inflammatory substance, 1 to 5 parts, said anti-inflammatory substance being selected from the amino sugars glucoomine, D-mannosamine, D-galactosamine, their biocompatible acid addition salts, glucosamine-6-phosphate, N-acetyl-D-gluccasmine, N-acetyl-D-galactosamine, and UDP-N-acetylglucosamine, the sugars 2-deoxy-D-glucose, 2-deoxy-D-galactose and mannose, and the amino acids cysteine, creatine, creatinine, L-tryptophan, valine, alanine, glycine, glutamine, aspartic acid, and S-methylcysteine; in which method the ascorbic acid, the phenylalanine or tyrosine, and the anti-inflammatory agent are administered topically and the calcium source is administered orally or topically in amounts effective to reduce or prevent tissue degenerative effects of wound-stimulated inflammation and to promote connective tissue growth.
Claim 2
Independent Claim
183 words
A method for accelerating wound healing in an animal or human having a wound in body tissue caused by trauma or surgery, which method comprises administration of the following substances in the relative weight proportions indicated: ascorbic acid, 1 to 5 parts; biologically available calcium, 2 to 10 parts provided by a calcium source selected from the group consisting of bone meal, biologically compatible calcium salts and calcium-containing foods; a precursor or stimulant of epinephrine or nor-epinephrine selected from tyrosine and phenylalanine, 0.5 to 2.5 parts; and an anti-inflammatory substance, 1 to 5 parts, said anti-inflammatory substance being selected from the amino sugars glucoomine, D-mannosamine, D-galactosamine, their biocompatible acid addition salts, glucosamine-6-phosphate, N-acetyl-D-gluccasmine, N-acetyl-D-galactosamine, and UDP-N-acetylglucosamine, the sugars 2-deoxy-D-glucose, 2-deoxy-D-galactose and mannose, and the amino acids cysteine, creatine, creatinine, L-tryptophan, valine, alanine, glycine, glutamine, aspartic acid, and S-methylcysteine; in which method the ascorbic acid, the phenylalanine or tyrosine, and the anti-inflammatory agent are administered topically and the calcium source is administered orally or topically in amounts effective to reduce or prevent tissue degenerative effects of wound-stimulated inflammation and to promote connective tissue growth.
Claim 3
Dependent Claim
57 words
The method of claim 1 wherein the administration of the biologically available calcium is provided by the animal's daily ingestion of substances selected from calcium-containing foods, bone meal and biologically compatable calcium salts in an amount sufficient to provide an average of at least 10 milligrams of biologically available calcium for every kilogram of animal body weight.
Claim 4
Dependent Claim
16 words
The method of claim 1 wherein the precursor or stimulant of epinephrine or nor-epinephrine is tyrosine.
Claim 5
Dependent Claim
13 words
The method of claim 3 wherein the anti-inflammatory substance is an amino acid.
Claim 6
Dependent Claim
11 words
The method of claim 4 wherein the anti-inflammatory agent is cysteine
Claim 7
Dependent Claim
18 words
The method of claim 3 wherein the anti-inflammatory agent is glucosamine or a biocompatible acid addition salt thereof.
Claim 8
Dependent Claim
22 words
The method of claim 1 wherein the source of biologically available calcium is selected from bone meal and biologically compatible calcium salts.
Claim 9
Dependent Claim
39 words
The method of claim 7 wherein the ascorbic acid, the source of biologically available calcium, the precursor or stimulant of epinephrine or nor-epinephrine and the anti-inflammatory substance are applied to the wound typically in a tissue compatible vehicle therefor.
Claim 10
Dependent Claim
16 words
The method of claim 8 wherein the precursor or stimulant of epinephrine or nor-epinephrine is tyrosine.
Claim 11
Dependent Claim
13 words
The method of claim 9 wherein the anti-inflammatory substance is an amino acid.
Claim 12
Dependent Claim
11 words
The method of claim 10 wherein the anti-inflammatory agent is cysteine.
Claim 13
Dependent Claim
18 words
The method of claim 9 wherein the anti-inflammatory agent is glucosamine or a biocompatible acid addition salt thereof.
References Cited (Backward Citations)
US3232836A
Cited
US4006224A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-09-20 | 1992-03-21 | 1992-09-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-09-20 | 1996-03-21 | 1996-09-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-09-20 | 2000-03-21 | 2000-09-20 | $7700.00 | Window Closed / Lapsed |